CAS: 125678-52-6; N,N-Diethylprop-2-Yn-1-Amine Formate

该化合物是一种化学化合物,其结构特征是其结构,包括附属于具有两种乙基替代成分的矿物质功能组的丙酰基体组;作为激进电离,它拥有一种未受保护的电子,在某些条件下有助于其反应性和稳定性;该化合物可能具有氨和激进物种的典型特性,如核分裂性和参与电子转移反应的能力;乙基组的存在可能影响其发育障碍和溶解于各种溶剂;此外,激进离子经常参与各种化学过程,包括聚合和再氧化反应;这种极离子的稳定可能受到温度和其他反应物种的存在等因素的影响;总体而言,2-丙平-1-胺,N,N-二乙基-,基离子(1+)代表一种独特的化合物类别,有可能应用于有机合成和材料科学.

结构式图片

MSDS等安全信息

    上下游产品

    diethyl-(2-bromo-allyl)-amine 6-diethylamino-3-methyl-hex-4-yn-3-ol sodium methylate 2-propynyl chlorideN,N-diethylhept-2-yn-1-amine N,N-diethyl-2-butin-1-ylamine diethyl-°Ct-2-ynyl-amine 1-cyclohexyl-4-diethylamino-1-phenyl-but-2-yn-1-ol

    合成工艺路线路线简述

      海关参考信息

      专利信息


      专利号:US-8487109-B2
      优先权日:2007-07-03
      标题:Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates
      发明人:RKYEK OMAR; NAZARE MARC; LINDENSCHMIDT ANDREAS; URMANN MATTHIAS; HALLAND NIS; ALONSO JORGE
      权利人:RKYEK OMAR; NAZARE MARC; LINDENSCHMIDT ANDREAS; URMANN MATTHIAS; HALLAND NIS; ALONSO JORGE; SANOFI SA
      摘要:The present invention relates to a process for the regioselective synthesis of compounds of the formula (I), n nwherein R1; R2; R3; R4; R5; J and W have the meanings indicated in the claims. The present invention provides an efficient and general palladium-catalyzed coupling process for aryl tosylates with terminal alkynes to a wide variety of substituted, multifunctional aryl-1-alkynes of the formula I.

      专利号:US-8420812-B2
      优先权日:2007-07-03
      标题:Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates
      发明人:RKYEK OMAR; NAZARE MARC; LINDENSCHMIDT ANDREAS; ALONSO JORGE; URMANN MATTHIAS; HALLAND NIS
      权利人:RKYEK OMAR; NAZARE MARC; LINDENSCHMIDT ANDREAS; ALONSO JORGE; URMANN MATTHIAS; HALLAND NIS; SANOFI SA
      摘要:A process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates n The present invention relates to a process for the regioselective synthesis of compounds of the formula (I), n nwherein D, J and W have the meanings indicated in the claims. The present invention provides an efficient and general palladium-catalyzed coupling process of heteroaryl tosylates with terminal alkynes to a wide variety of substituted, multifunctional heteroaryl-1-alkynes of the formula I.

      专利号:WO-2023091726-A1
      优先权日:2021-11-18
      标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
      发明人:BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
      权利人:SYROS PHARMACEUTICALS INC
      摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

      专利号:EP-1776333-B1
      优先权日:2004-07-21
      标 题:Ammonium salts and ammonium salt/mineral salt clathrate compounds for use as vehicle and effective form for pharmaco-medical applications and for use as phase transfer agents for chemical applications
      发明人:REUTER UWE; OETTMEIER RALF; KASCH HELMUT
      权利人:KASCH HELMUT
      摘要:This invention relates to ammonium salts and stable storable ammonium salts and ammonium salt/mineral salt clathrate compounds (inclusion compounds, clusters) having acid dibasic anionic acid residues such as bicarbonate, to methods for producing them and to pharmaco-medical and chemical synthetic applications for said compounds. According to the invention, compounds for pharmaco-medical and chemical synthetic applications are produced which comprise the ammonium salt and ammonium salt/mineral salt clathrate compounds (inclusion compounds, clusters) having acid dibasic anionic acid residues of general formula I with R1, R2, R3 and R4=alkyl and substituted alkyl straight-chain or branched, optionally having an alcohol, ether, silyether, ester, amino or amide function, H or aryl-alkyl, with aryl being an aromatic or heteroaromatic ring having optionally additional substituents, such as alkyl having 1 to 4 C atoms, OH, NR*2 with R*2=O, alkyl with alkyl of between 1 and 4 C atoms or H, COOH, COOR, CN, NO2 and the cationic positive N+ is optionally part of an active agent, Y is a dibasic acid residue of an organic dicarboxylic acid or CO3-, corresponding to HY-=HCO3-, and x=0.5 to 30 represents the number of the mineral salt molecules for clathrate compound formation or 0. In pharmaco-medical applications applies the generalizable effectiveness principle according to which to ammonium salt/mineral salt cluster is used as vehicle and active agent for novel forms of application of nitrogen-containing active agent bases. In chemistry, these agents are used in the synthesis of active agents and valuable products, e.g. of cyclic carbonates.

      专利号:WO-03061385-A1
      优先权日:2002-01-17
      标题:Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
      发明人:AN HAOYUN; HONG ZHI; SMITH KENNETH; DING YILI; GIRARDET JEAN-LUC
      权利人:RIBAPHARM INC; AN HAOYUN; HONG ZHI; SMITH KENNETH; DING YILI; GIRARDET JEAN-LUC
      摘要:Tricyclic nucleoside libraries and library compounds are prepared using combinatorial chemistry and non-combinatorial chemistry methods. Contemplated library compounds are particularly useful in inhibition of viral propagation, and particularly of viral propagation of the HCV virus.

      专利号:CN-102180798-A
      优先权日:2011-03-18
      标题 :Method for one-step catalytic synthesis of N,N-diethylpropynylamine
      江苏梦得电镀化学品有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.chinamengde.com
      电话: 0086 (511) 8686-2404 / 8686-4808👤
      📞江苏梦得电镀化学品有限公司 ⚠️参考联系方式

      销售电话:0086 (511) 8686-2404 / 8686-4808
      邮箱:david2262000@126.com
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      湖北和昌化工有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.whhechang.cn
      电话: 0086 15926257337👤
      📞湖北和昌化工有限公司 ⚠️参考联系方式

      销售电话:0086 15926257337
      邮箱:whhc@whhechang.cn
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      武汉市罗氏科技发展有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.luoshikg.com
      企业联系电话:18986168071;19307247857👤
      📞武汉市罗氏科技发展有限公司 ⚠️参考联系方式
      联系人:罗经理;祝经理
      电话:18986168071;19307247857
      手机:18986168071;19307247857
      传真:027-88121016;QQ1712680783
      邮箱:18986168071@163.com
      通信地址: 湖北省武汉市洪山区洪山工业园
      邮编: 430064
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      地址:湖北省武汉市洪山区洪山工业园
      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
      ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      武汉吉和昌新材料股份有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.jadechem.com
      企业联系电话:18602737196👤
      📞武汉吉和昌新材料股份有限公司 ⚠️参考联系方式
      联系人:胡培
      电话:18602737196
      手机:18602737196
      传真:027-83551196
      邮箱:907420791@qq.com
      通信地址: 武汉市青山区化学工业园化工大道130号
      邮编: 430023
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      地址:武汉市青山区化学工业园化工大道130号
      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
      ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      武汉松石科技股份有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.wh-pinestone.com
      企业联系电话:027-85880528👤
      📞武汉松石科技股份有限公司 ⚠️参考联系方式
      联系人:杨经理
      电话:027-85880528
      手机:027-85880528

      邮箱:sales@wh-pinestone.com
      通信地址: 武汉市江岸区京汉大道1268号铂仕汇国际广场22楼2208室
      邮编:
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      地址:武汉市江岸区京汉大道1268号铂仕汇国际广场22楼2208室
      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
      ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      第 1 / 1 页
      现货

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      合成参考文献


      摘要:Schatz, J.; Seßler, M., Science of Synthesis Knowledge Updates, (2010) 1, 105.
      摘要:Dong, X.; Liu , H., Science of Synthesis Knowledge Updates, (2019) 3, .
      摘要:Liang, Y.; Wen, Z.; Cabrera, M.; Howlader, A. H.; Wnuk, S. F., Science of Synthesis Knowledge Updates, (2020) 1, 340.
      摘要:Cuenca, A. B.; Fernández, E., Science of Synthesis: N-Heterocyclic Carbenes in Catalytic Organic Synthesis, (2016) 1, 324.
      摘要:Toxicology and Applied Pharmacology., 28(313), 1974 []
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知